SCHEMBL27213280

SCHEMBL27213280

C[C@@H]1CN(C(=O)O)CC[C@@H]1Nc1ncc(C(F)(F)F)c(-c2cc(C(N)=O)cs2)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 6/20 0.40
▸ CDK4 P11802 3/20 0.38
▸ CCND1 P24385 3/20 0.38
▸ CCND3 P30281 3/20 0.38
▸ CDK6 Q00534 3/20 0.38
▸ LCK P06239 2/20 0.38
▸ MAPK3 P27361 1/20 0.36
▸ CCNK O75909 8/20 0.35
▸ CDK12 Q9NYV4 8/20 0.35
▸ CCNE1 P24864 4/20 0.35
▸ CDK2 P24941 4/20 0.35
▸ CCNT1 O60563 3/20 0.35
▸ CDK9 P50750 3/20 0.35
▸ CDK7 P50613 3/20 0.35
▸ CCNH P51946 3/20 0.35
▸ MNAT1 P51948 3/20 0.35
▸ KIT P10721 2/20 0.34
▸ FLT3 P36888 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27392414 0.91 CDK4 (0.43) JAK3CDK4CCND1CCND3CDK6
SCHEMBL27392409 0.91 CDK4 (0.43) JAK3CDK4CCND1CCND3CDK6
SCHEMBL30906884 0.87 CDK6 (0.47) CDK4CCND1CCND3CDK6MAPK3
SCHEMBL27213229 0.87 CDK6 (0.47) CDK4CCND1CCND3CDK6MAPK3
SCHEMBL30906921 0.82 CCNK (0.45) CCNKCDK12CCNE1CDK2CCNT1
SCHEMBL27213287 0.82 CCNK (0.45) CCNKCDK12CCNE1CDK2CCNT1
SCHEMBL27392474 0.82 CCNK (0.45) CCNKCDK12CCNE1CDK2CCNT1
SCHEMBL30906842 0.82 CDK2 (0.50) JAK3CDK4CCND1CCND3CDK6
SCHEMBL30906883 0.82 CCNE1 (0.38) JAK3CDK4CCND1CCND3CDK6
SCHEMBL27213255 0.82 CCNE1 (0.38) JAK3CDK4CCND1CCND3CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150340-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-05-09 — — US disclosed
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150340-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 JAK3 226/4885CDK4 12/4885CCND1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback